Last updated: 18 March 2024 at 4:33pm EST

Steven Paul Net Worth




The estimated Net Worth of Steven M Paul is at least $65.7 Million dollars as of 23 February 2024. Steven Paul owns over 31,518 units of Karuna Therapeutics Inc stock worth over $13,890,461 and over the last 19 years he sold KRTX stock worth over $41,762,013. In addition, he makes $10,050,700 as Chairman of the Board, President, and Chief Executive Officer at Karuna Therapeutics Inc.

Steven Paul KRTX stock SEC Form 4 insiders trading

Steven has made over 35 trades of the Karuna Therapeutics Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 31,518 units of KRTX stock worth $599,788 on 23 February 2024.

The largest trade he's ever made was exercising 292,207 units of Karuna Therapeutics Inc stock on 29 June 2020 worth over $32,143. On average, Steven trades about 10,944 units every 74 days since 2005. As of 23 February 2024 he still owns at least 42,114 units of Karuna Therapeutics Inc stock.

You can see the complete history of Steven Paul stock trades at the bottom of the page.





Steven Paul biography

Dr. Steven M. Paul M.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Previously, Dr. Paul was the President and Chief Executive Officer of Voyager Therapeutics, Inc. from September 2014 to August 2018. Dr. Paul also serves as a venture partner at Third Rock Ventures, LLC, a life sciences venture capital firm. Together with Third Rock, Dr. Paul co-founded Sage Therapeutics, Inc. and Voyager Therapeutics, Inc. From August 2010 to September 2014, Dr. Paul was a professor of neuroscience, psychiatry and pharmacology at Weill Cornell Medical College. Prior to that, from 1993 to 2010, Dr. Paul held several key positions at Eli Lilly and Company, or Eli Lilly, including Executive Vice President for Science and Technology, President of the Lilly Research Laboratories, Vice President of Neuroscience (CNS) Research and Group Vice President of Discovery Research. Prior to Eli Lilly, from 1988 to 1993, Dr. Paul served as the Scientific Director of the National Institute of Mental Health, or NIMH. From 1982 to 1988 Dr. Paul served as a laboratory branch chief and tenured investigator at NIMH. Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. Dr. Paul is currently on the board of directors or is a trustee of several organizations, including Sage Therapeutics, Inc. (NASDAQ: SAGE), Voyager Therapeutics, Inc. (NASDAQ: VYGR), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and the Foundation for the National Institutes of Health, or FNIH. In the past five years, Dr. Paul also served on the board of Sigma Aldrich Corporation (NASDAQ: SIAL). Dr. Paul was appointed by the Secretary of the Department of Health and Human Services as a member of the advisory committee to the Director of the NIH from 2001 to 2006.

What is the salary of Steven Paul?

As the Chairman of the Board, President, and Chief Executive Officer of Karuna Therapeutics Inc, the total compensation of Steven Paul at Karuna Therapeutics Inc is $10,050,700. There are no executives at Karuna Therapeutics Inc getting paid more.



What's Steven Paul's mailing address?

Steven's mailing address filed with the SEC is C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON, MA, 02110.

Insiders trading at Karuna Therapeutics Inc

Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy, and Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.



What does Karuna Therapeutics Inc do?

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip



What does Karuna Therapeutics Inc's logo look like?

Karuna Therapeutics Inc logo

Complete history of Steven Paul stock trades at Alnylam Pharmaceuticals Inc, Sage Therapeutics Inc, Voyager Therapeutics Inc, Lilly(Eli) & Co, and Karuna Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
23 Feb 2024 Steven M Paul
Option 31,518 $19.03 $599,788
23 Feb 2024
42,114
17 Aug 2021 Steven M Paul
Buy 2,364 $105.86 $250,253
17 Aug 2021
108,849
29 Jun 2020 Steven M Paul
Option 292,207 $0.11 $32,143
29 Jun 2020
398,692
27 Jun 2019 Steven M Paul
Buy 10,000 $23.04 $230,400
27 Jun 2019
10,000
1 Apr 2022 Steven M Paul
Director
Option 15,000 $11.33 $169,950
1 Apr 2022
16,000
18 Dec 2020 Steven M Paul
Director
Option 15,000 $9.30 $139,500
18 Dec 2020
16,000
10 Feb 2020 Steven M Paul
Director
Option 30,000 $14.67 $440,100
10 Feb 2020
31,000
26 Jan 2015 Steven M Paul
Director
Buy 1,000 $95.00 $95,000
26 Jan 2015
1,000
21 Mar 2019 Steven M Paul
Sale 7,879 $161.04 $1,268,834
21 Mar 2019
122,400
18 Mar 2019 Steven M Paul
Sale 60,421 $161.28 $9,744,699
18 Mar 2019
130,279
1 Mar 2019 Steven M Paul
Sale 2,600 $161.00 $418,600
1 Mar 2019
190,700
25 Feb 2019 Steven M Paul
Sale 2,000 $161.00 $322,000
25 Feb 2019
70,900
15 Feb 2019 Steven M Paul
Sale 51,004 $161.04 $8,213,684
15 Feb 2019
72,900
6 Mar 2018 Steven M Paul
Sale 58,139 $172.00 $9,999,908
6 Mar 2018
632,712
1 Sep 2015 Steven M Paul
Sale 20,000 $52.41 $1,048,200
1 Sep 2015
683,650
3 Aug 2015 Steven M Paul
Sale 20,000 $67.08 $1,341,600
3 Aug 2015
703,650
1 Jul 2015 Steven M Paul
Sale 20,000 $69.40 $1,388,000
1 Jul 2015
723,650
1 Jun 2015 Steven M Paul
Sale 20,000 $72.34 $1,446,800
1 Jun 2015
743,650
1 Apr 2015 Steven M Paul
Sale 20,000 $48.51 $970,200
1 Apr 2015
783,650
23 Jul 2014 Steven M Paul
Buy 10,000 $18.00 $180,000
23 Jul 2014
803,650
14 Jan 2016 Steven M Paul
Director
Buy 10,000 $14.07 $140,700
14 Jan 2016
872,351
1 Feb 2010 Steven M Paul
EVP, Science, and Technology
Option 51,249 $35.00 $1,793,715
1 Feb 2010
56,249
1 Feb 2008 Steven M Paul
EVP, Science, and Technology
Sale 19,822 $51.60 $1,022,815
1 Feb 2008
50,300
21 May 2007 Steven M Paul
EVP, Science, and Technology
Option 98,008 $54.80 $5,370,838
21 May 2007
138,140
15 May 2007 Steven M Paul
EVP, Science, and Technology
Option 1,992 $54.80 $109,162
15 May 2007
42,032
12 Mar 2007 Steven M Paul
EVP, Science, and Technology
Sale 7,289 $52.39 $381,871
12 Mar 2007
1,070
12 Feb 2007 Steven M Paul
EVP, Science, and Technology
Sale 7,290 $54.38 $396,430
12 Feb 2007
8,359
8 Feb 2007 Steven M Paul
EVP, Science, and Technology
Sale 10,092 $54.32 $548,197
8 Feb 2007
54,619
20 Oct 2006 Steven M Paul
EVP, Science, and Technology
Sale 4,836 $56.91 $275,217
20 Oct 2006
1,070
15 Sep 2006 Steven M Paul
EVP, Science, and Technology
Option 2,890 $34.60 $99,994
15 Sep 2006
42,546
25 Apr 2006 Steven M Paul
EVP, Science, and Technology
Sale 25,000 $52.06 $1,301,500
25 Apr 2006
39,656
21 Apr 2006 Steven M Paul
EVP, Science, and Technology
Sale 25,000 $52.80 $1,320,000
21 Apr 2006
64,656
2 Feb 2006 Steven M Paul
EVP, Science, and Technology
Sale 6,201 $57.00 $353,457
2 Feb 2006
89,656
15 Dec 2005 Steven M Paul
EVP, Science, and Technology
Option 13,110 $34.59 $453,475
15 Dec 2005
90,202
13 Oct 2005 Steven M Paul
EVP, Science, and Technology
Option 24,000 $23.41 $561,840
13 Oct 2005
40,827


Karuna Therapeutics Inc executives and stock owners

Karuna Therapeutics Inc executives and other stock owners filed with the SEC include: